Focus:
Five months after suspected carcinogens were first discovered in valsartan API produced by two Chinese CMOs, the contamination is now known to be a much larger problem, as Teva (Petah...
In this issue: A new class of cancer combo treatments, antidepressants in the environment, microbiome-based drug development, and more.
Verzenio's Phase II trial should start in early 2019 after funding was approved by sponsor Eli Lilly.
Johnson & Johnson's Phase III data of Darzalex (daratumumab) in front-line multiple myeloma (MM) could have an immediate impact on clinical practice in the US.
AstraZeneca has partnered with Cancer Research UK to open a functional genomics centre of excellence focused on accelerating the discovery and development of new oncology medicines.
Data from the Phase III AUGMENT trial assessing Revlimid plus rituximab in relapsed/refractory (R/R) indolent lymphoma was presented during the second day of the 2018 American Society of Hematology (ASH)...
Breast cancer is the most commonly diagnosed cancer in women and the second most commonly diagnosed cancer overall.
Pfizer is gearing up to commercialise its four new brands as quickly as they were approved in order to build up new revenue that will offset the impending revenue loss...
A new report by The Institute of Cancer Research, London (ICR) has revealed an increase of nearly one year in delay between clinical trials, regulatory approvals and patient access to...
GlaxoSmithKline (GSK) has signed a merger agreement to buy US-based biopharmaceutical company Tesaro for an aggregate consideration of around $5.1bn in a cash-based transaction.
